Novartis receives three new FDA approvals for the expanded use of Ilaris

Swiss pharma giant Novartis (NOVN: VX) says that the US Food and Drug Administration has granted three simultaneous approvals for the expanded use of Ilaris(canakinumab) to treat three rare and distinct types of periodic fever syndromes.

Ilaris, which generated first-half 2016 sales of $135 million, is the first and only FDA-approved biologic treatment for tumor necrosis factor-receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD) and familial Mediterranean fever (FMF).

"Gaining three simultaneous FDA approvals of Ilaris is a momentous turning point for people who suffer with these severe, debilitating diseases"